NASDAQ · MRVI
Maravai LifeSciences Holdings, Inc.
$8.46-$0.04 (-0.47%)
Maravai LifeSciences Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.19% below the high.
Loading market information…
NASDAQ · LENZ · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
LENZ Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.14% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
LENZ Therapeutics, Inc.’s forward annual dividend is $374.92 per share, paid weekly. The forward yield is 10,742.69% at the quoted price. Future payments can change.
Dividend payment history is currently unavailable.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
LENZ Therapeutics, Inc.’s next earnings report is currently expected on Mar 23, 2027, with estimated earnings per share of -$0.86. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow LENZ Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:27 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Jul 30, 2025 | -$0.53+8.62% vs estimate | $5.00M+600.0% vs estimate |
|---|
| Q1 2025 | May 7, 2025 | -$0.53+3.64% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q4 2024 | Mar 19, 2025 | -$0.46-9.52% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $5.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$8.46-$0.04 (-0.47%)
Maravai LifeSciences Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.19% below the high.
$33.80-$0.18 (-0.53%)
Nanobiotix S.A.’s quoted price sits in the lower half of its reported 52-week range, 40.85% below the high.
$21.50+$0.79 (+3.81%)
GH Research PLC’s quoted price sits in the lower half of its reported 52-week range, 31.62% below the high.
$21.48-$0.27 (-1.24%)
Tyra Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.16% below the high.
$4.95-$0.07 (-1.39%)
Savara Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.39% below the high.
$5.24-$0.12 (-2.24%)
Prime Medicine, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.34% below the high.
$4.28-$0.04 (-0.93%)
Arbutus Biopharma Corp’s quoted price sits in the lower half of its reported 52-week range, 21.47% below the high.
$0.95-$0.02 (-2.3%)
Geron Corporation’s quoted price sits in the lower half of its reported 52-week range, 52.93% below the high.
